Perifosine

Perifosine

SCHEMBL93872

CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 10/20 1.00
TERT O14746 1/20 1.00
UCHL3 P15374 1/20 1.00
MAPK14 Q16539 1/20 1.00
CDC25A P30304 2/20 0.51
LMNA P02545 2/20 0.50
ESR1 P03372 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
AGTR1 P30556 1/20 0.50
ADRA1A P35348 1/20 0.50
KCNH2 Q12809 1/20 0.50
PRKD3 O94806 1/20 0.40
PRKCG P05129 1/20 0.40
PRKCB P05771 1/20 0.40
PRKCA P17252 1/20 0.40
PRKCH P24723 1/20 0.40
PRKCI P41743 1/20 0.40
PRKCE Q02156 1/20 0.40
PRKCQ Q04759 1/20 0.40
PRKCZ Q05513 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22942075 1.00 AKT1 (1.00) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL9407417 0.95 AKT1 (0.90) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL29549430 0.85 AKT1 (0.74) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL17789850 0.84 AKT1 (0.72) AKT1TERTUCHL3MAPK14CDC25A
Perifosine SCHEMBL6075387 0.83 AKT1 (0.71) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL14447963 0.83 AKT1 (0.71) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL14447962 0.83 AKT1 (0.71) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL14447952 0.83 AKT1 (0.71) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL14447863 0.83 AKT1 (0.71) AKT1TERTUCHL3MAPK14CDC25A
SCHEMBL14492081 0.82 AKT1 (0.69) AKT1TERTUCHL3MAPK14CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 15993 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636376-B2 Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors IN3BIO LTD. (BM) 2026-05-26 US claimed
US-20260139320-A1 StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine UNIV OF SOUTH CAROLINA (US) 2026-05-21 US claimed
EP-4743565-A2 CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES Iovance Biotherapeutics, Inc. (US) 2026-05-20 EP claimed
CN-122028938-A Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor 德彪药业国际股份公司 2026-05-12 CN claimed
EP-3645742-B1 ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF SYSTIMMUNE INC (US) 2026-04-29 EP claimed
EP-4732908-A2 CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS Biomed Valley Discoveries, Inc. (US) 2026-04-29 EP claimed
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2026-04-23 US claimed
EP-4363043-B1 COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS NOVOCURE GMBH (CH) 2026-04-22 EP claimed
US-20260103461-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF OLEMA PHARMACEUTICALS INC (US) 2026-04-16 US claimed
US-20260097028-A1 Methods of Treating Myeloproliferative Neoplasms KARTOS THERAPEUTICS INC (US) 2026-04-09 US claimed
US-20050227266-A1 Biomarker:compound correlations in cancer diagnosis and therapy APPLIED GENOMICS, INC. 2005-10-13 US claimed
WO-2005085863-A2 BIOMARKER: COMPOUND CORRELATIONS IN CANCER DIAGNOSIS AND THERAPY APPLIED GENOMICS, INC. (US) 2005-09-15 WO claimed
WO-2005063278-A1 SURFACE PROTECTION OF EXPOSED BIOLOGICAL TISSUES BIOACTIVE POLYMERS AB (SE) 2005-07-14 WO claimed
CN-1622811-A Use of alkylphosphocholines for the preventative treatment of protozoan diseases ZENTARIS AG (DE) 2005-06-01 CN claimed
CN-1617744-A Anti-tumor combination therapy comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors PHARMACIA ITALIA SPA (IT) 2005-05-18 CN claimed
EP-1461083-A1 COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-09-29 EP claimed
US-20040097470-A1 Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals ZENTARIS GMBH (DE) 2004-05-20 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
WO-2003055522-A1 COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS PHARMACIA ITALIA SPA (IT) 2003-07-10 WO claimed
EP-1135193-B1 AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN MAX DELBRUECK CENTRUM (DE) 2002-10-30 EP claimed